ClinicalTrials.gg
Not yet recruitingNCT07942038Updated Nov 17, 2026

Myocardial Fibrosis and Deformation Kinetics After the Ross Procedure Using Cardiac MRI

An observational study in Ross Operation, sponsored by Assiut University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Assiut University · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
44
Sex
All
01

Study summary

The Ross procedure entails pulmonary autograft replacement of the aortic valve, primarily indicated in pediatric and young adult cohorts presenting with severe aortic valve disease. Despite postoperative preservation of left ventricular ejection fraction (LVEF) on resting transthoracic echocardiography, a subset of recipients exhibits blunted peak oxygen consumption (peak VO2), subclinical electromechanical dyssynchrony, and ventricular arrhythmias.

Chronic severe aortic valve pathology induces distinct myocardial remodeling patterns. Chronic pressure overload (aortic stenosis) triggers concentric cardiomyocyte hypertrophy and diffuse interstitial fibrosis. Chronic volume overload (aortic regurgitation) induces eccentric left ventricular dilatation and extracellular matrix degradation with collagen disarray. Following surgical hemodynamic unloading, left ventricular mass regresses; however, the extent of diffuse interstitial collagen matrix resorption versus pure cardiomyocyte cellular volume regression remains uncharacterized in this demographic.

This prospective longitudinal study employs multiparametric cardiovascular magnetic resonance (CMR) imaging to evaluate myocardial tissue characterization and deformation kinetics in young adults undergoing the Ross procedure. Participants will undergo contrast-enhanced CMR at baseline and at 12 months postoperatively. Quantitative endpoints include native T1 mapping, extracellular volume fraction (ECV), indexed extracellular volume (iECV), and three-dimensional (3D) feature-tracking strain (global longitudinal, circumferential, and radial strain). The primary objective is to correlate the resolution of diffuse microscopic fibrosis with subclinical mechanical recovery, comparing remodeling trajectories between pressure-overloaded and volume-overloaded phenotypes.

02

Conditions studied

  • Ross Operation
03

In context

Lead sponsor

Assiut University is the lead sponsor of 5,088 studies on the registry; 2,185 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population comprises patients presenting with severe primary aortic valve disease-specifically chronic pressure overload (severe aortic stenosis) or chronic volume overload (severe aortic regurgitation)-who are scheduled for an elective full-root Ross procedure (pulmonary autograft replacement of the aortic valve). Patients are recruited prospectively and are evaluated without a history of obstructive coronary artery disease, prior myocardial infarction, primary non-ischemic cardiomyopathy, or systemic connective tissue disorders.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Severe primary aortic valve stenosis, regurgitation, or mixed lesion scheduled for an elective Ross procedure.
  2. Informed written consent to participate in serial prospective imaging.

Exclusion criteria

Exclusion Criteria:

  1. Documented coronary artery disease (≥ 50% stenosis or previous coronary revascularization).
  2. Prior myocardial infarction or primary non-ischemic cardiomyopathy.
  3. Severe renal impairment (estimated \< 30 mL/min/1.73 m²).
  4. Associated congenital heart disease causing volume overload ex: VSD and PDA.
  5. Systemic connective tissue disorders (Marfan, Loeys-Dietz, or Ehlers-Danlos syndromes).
  6. Standard to contrast-enhanced CMR (incompatible ferromagnetic implants, severe claustrophobia).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
44 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Diffuse myocardial fibrosis

    Quantify the serial longitudinal changes in diffuse myocardial interstitial fibrosis-measured by indexed extracellular volume (iECV, in mL/m²)-from baseline to 12 months postoperatively in young adults undergoing the Ross procedure.

    Time frame: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.

  2. Diffuse myocardial fibrosis

    Quantify the serial longitudinal changes in diffuse myocardial interstitial fibrosis-measured by extracellular volume fraction (ECV, in %)

    Time frame: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.

Secondary outcomes

  1. Subclinical myocardial mechanical recovery

    Measured by 3D CMR feature-tracking strain analysis by 3D global longitudinal strain (3D-GLS)

    Time frame: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.

  2. Subclinical myocardial mechanical recovery

    Measured by 3D CMR feature-tracking strain analysis by 3D global circular strain (3D-GCS)

    Time frame: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.

  3. Subclinical myocardial mechanical recovery

    Measured by 3D CMR feature-tracking strain analysis by global radial strain \[GRS\].

    Time frame: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.

  4. Subclinical myocardial mechanical recovery

    Measured through 3D CMR feature-tracking strain analysis by peak diastolic strain rate.

    Time frame: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2027; primary completion for Dec 2028, 19 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2026
First posted
Nov 17, 2026
StartEst.
May 2027
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07942038
Lead sponsor
Assiut University
Responsible party
Yomna Mahmoud Shokry Abdelrehim (Assistant lecturer at cardiology department, Assiut university Hospitals, Assiut University) — Principal investigator
First posted
Nov 17, 2026
Start date
May 2027 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion